uMedical
Medicines
Substances
Companies
Statistics
Menu
All medicines
Mirvaso
Authorised
Human
Details
EMA number
EMEA/H/C/002642
ATC code
D11AX21
Authorisation
20 February 2014
Revision
14
EMA page
Therapeutic indication
Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.
MeSH:
Skin Diseases
Group:
Other dermatological preparations
Active substances
brimonidine tartrate
Marketing Authorisation Holder
Galderma International
MAH
Timeline
Filter by authority:
EMA
Mirvaso authorised
20 Feb 2014
authorised
regulatory
Mirvaso | uMedical